RE:RE:COULD NOT RVX DONE THE SAME WITH ???????quest13, you have said it extremely well. That is exactly my situation. Also, I am accumulating RVX slowly when I have the opportunity to buy some.
I'm accumulating up and as the run up comes for the next regional deal, the orphan trial or completion of the futility results I'm taking some profit and then sitting back and waiting for BETonMACE but in the run up to those results there will be a run up in share price also. I'm not a trader but I'll take a bit of profit at each stage. I don't need to be greedy.
I do agree with you on a few key key points;
- Don is shaping this to be a downstream company (e.g. Hepalink and the next regional deal). If BP comes in with a huge offer in the meantime then so be it. At the Zenith update he even said a suitor could write 1 cheque or 2 (RVX or Zenith or both).
- Eastern/KD, NGN, Hepalink, Don, Dr Wong and the next regional partner are in this for billions of dollars of return over the long run both through RVX, Zenith Epigenetics and Zenith Capital.
- People holding shares like RVX are in for the run through 2018 with various opportunities in between as noted.
Anything can fail such as the hundreds of millions invested in CEPT inhibitors. However, from my perspective, the scientific discoveries about BET inhibition and the RVX and Zenith methods, since June of 2013 have been nothing but positive and there have been no setbacks in that period.
The scientific talent in the BETonMACE steering committee is exceptional. The fact that the scientists at Eastern, NGN and Hepalink have analysed rvx-208(apabetalone) independently and still give their votes of confidence is a strong indication that very bright minds have analysed this drug and science and believe in it's potential.
Don indicated that RVX has 2500 compunds developed. Some of these could make it to trials and Zenith has 1400 compounds/molecules developed.
This company is not just about having 1 molecule. It is about an entire science of BET inhibition and the applications are many and diverse.
Existing patents are extensive.
So I remain long.
GLTA
Toinv